The DOI matches its Crossref record; 165 of the 165 references it cites were found in a registry or an index.
Exploiting the PI3K/AKT Pathway for Cancer Drug Discovery
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Dan, H. C., Sun, M., Yang, L., Feldman, R. I., Sui, X.-M., Ou, C. C., Nellist, M., Yeung, R. S., Halley, D. J. J., Nicosia, S. V., et al. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m205838200 · Cited by 370
RetractedHanahan, D., & Weinberg, R. A. (2000) · Cell · doi:10.1016/s0092-8674(00)81683-9 · Cited by 29,219
Slamon, D. J., Leyland-Jones, B., Shak, S., Fuchs, H., Paton, V., Bajamonde, A., Fleming, T., Eiermann, W., Wolter, J., Pegram, M., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200103153441101 · Cited by 11,500
Lynch, T. J., Bell, D. W., Sordella, R., Gurubhagavatula, S., Okimoto, R. A., Brannigan, B. W., Harris, P. L., Haserlat, S. M., Supko, J. G., Haluska, F. G., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa040938 · Cited by 11,486
Mutations of the BRAF gene in human cancer
Davies, H., Bignell, G. R., Cox, C., Stephens, P., Edkins, S., Clegg, S., Teague, J., Woffendin, H., Garnett, M. J., Bottomley, W., et al. (2002) · Nature · doi:10.1038/nature00766 · Cited by 10,674
EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy
Paez, J. G., Jänne, P. A., Lee, J. C., Tracy, S., Greulich, H., Gabriel, S., Herman, P., Kaye, F. J., Lindeman, N., Boggon, T. J., et al. (2004) · Science · doi:10.1126/science.1099314 · Cited by 9,368
Studies of the HER-2/ neu Proto-Oncogene in Human Breast and Ovarian Cancer
Slamon, D. J., Godolphin, W., Jones, L. A., Holt, J. A., Wong, S. G., Keith, D. E., Levin, W. J., Stuart, S. G., Udove, J., Ullrich, A., et al. (1989) · Science · doi:10.1126/science.2470152 · Cited by 6,816
Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex
Sarbassov, D. D., Guertin, D. A., Ali, S. M., & Sabatini, D. M. (2005) · Science · doi:10.1126/science.1106148 · Cited by 6,216
The phosphatidylinositol 3-Kinase–AKT pathway in human cancer
Vivanco, I., & Sawyers, C. L. (2002) · Nature Reviews Cancer · doi:10.1038/nrc839 · Cited by 6,056
Akt Promotes Cell Survival by Phosphorylating and Inhibiting a Forkhead Transcription Factor
Brunet, A., Bonni, A., Zigmond, M. J., Lin, M. Z., Juo, P., Hu, L. S., Anderson, M. J., Arden, K. C., Blenis, J., & Greenberg, M. E. (1999) · Cell · doi:10.1016/s0092-8674(00)80595-4 · Cited by 5,594
Li, J., Yen, C., Liaw, D., Podsypanina, K., Bose, S., Wang, S. I., Puc, J., Miliaresis, C., Rodgers, L., McCombie, R., et al. (1997) · Science · doi:10.1126/science.275.5308.1943 · Cited by 4,785
Blume-Jensen, P., & Hunter, T. (2001) · Nature · doi:10.1038/35077225 · Cited by 3,738
High Frequency of Mutations of the PIK3CA Gene in Human Cancers
Samuels, Y., Wang, Z., Bardelli, A., Silliman, N., Ptak, J., Szabo, S., Yan, H., Gazdar, A., Powell, S. M., Riggins, G. J., et al. (2004) · Science · doi:10.1126/science.1096502 · Cited by 3,437
Specificity and mechanism of action of some commonly used protein kinase inhibitors
DAVIES, S. P., REDDY, H., CAIVANO, M., & COHEN, P. (2000) · Biochemical Journal · doi:10.1042/bj3510095 · Cited by 3,132
Mechanism of activation of protein kinase B by insulin and IGF-1.
Alessi, D. R., Andjelkovic, M., Caudwell, B., Cron, P., Morrice, N., Cohen, P., & Hemmings, B. A. (1996) · The EMBO Journal · doi:10.1002/j.1460-2075.1996.tb01045.x · Cited by 3,004
Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells
Druker, B. J., Tamura, S., Buchdunger, E., Ohno, S., Segal, G. M., Fanning, S., Zimmermann, J., & Lydon, N. B. (1996) · Nature Medicine · doi:10.1038/nm0596-561 · Cited by 2,967
Glycogen synthase kinase-3β regulates cyclin D1 proteolysis and subcellular localization
Diehl, J. A., Cheng, M., Roussel, M. F., & Sherr, C. J. (1998) · Genes & Development · doi:10.1101/gad.12.22.3499 · Cited by 2,130
Most human carcinomas of the exocrine pancreas contain mutant c-K-ras genes
Almoguera, C., Shibata, D., Forrester, K., Martin, J., Arnheim, N., & Perucho, M. (1988) · Cell · doi:10.1016/0092-8674(88)90571-5 · Cited by 2,114
TOR, a Central Controller of Cell Growth
Schmelzle, T., & Hall, M. N. (2000) · Cell · doi:10.1016/s0092-8674(00)00117-3 · Cited by 1,924
Nagata, Y., Lan, K.-H., Zhou, X., Tan, M., Esteva, F. J., Sahin, A. A., Klos, K. S., Li, P., Monia, B. P., Nguyen, N. T., et al. (2004) · Cancer Cell · doi:10.1016/j.ccr.2004.06.022 · Cited by 1,858 · cited 1×
“PTEN activity contributes to the efficacy of trastuzumab (Herceptin; Genentech) and radiation therap”
BackgroundThe IκB-NF-κB Signaling Module: Temporal Control and Selective Gene Activation
Hoffmann, A., Levchenko, A., Scott, M. L., & Baltimore, D. (2002) · Science · doi:10.1126/science.1071914 · Cited by 1,858
Shaw, R. J., Kosmatka, M., Bardeesy, N., Hurley, R. L., Witters, L. A., DePinho, R. A., & Cantley, L. C. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0308061100 · Cited by 1,797
Causal Protein-Signaling Networks Derived from Multiparameter Single-Cell Data
Sachs, K., Perez, O., Pe'er, D., Lauffenburger, D. A., & Nolan, G. P. (2005) · Science · doi:10.1126/science.1105809 · Cited by 1,708
Emergent Properties of Networks of Biological Signaling Pathways
Bhalla, U. S., & Iyengar, R. (1999) · Science · doi:10.1126/science.283.5400.381 · Cited by 1,686
Gefitinib-Sensitizing EGFR Mutations in Lung Cancer Activate Anti-Apoptotic Pathways
Sordella, R., Bell, D. W., Haber, D. A., & Settleman, J. (2004) · Science · doi:10.1126/science.1101637 · Cited by 1,606
Fruman, D. A., Meyers, R. E., & Cantley, L. C. (1998) · Annual Review of Biochemistry · doi:10.1146/annurev.biochem.67.1.481 · Cited by 1,355
Targeting the PI3K-Akt pathway in human cancer
Luo, J., Manning, B. D., & Cantley, L. C. (2003) · Cancer Cell · doi:10.1016/s1535-6108(03)00248-4 · Cited by 1,290
Ultrasensitivity in the mitogen-activated protein kinase cascade.
Huang, C. Y., & Ferrell, J. E. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.19.10078 · Cited by 1,186
PIK3CA is implicated as an oncogene in ovarian cancer
Shayesteh, L., Lu, Y., Kuo, W.-L., Baldocchi, R., Godfrey, T., Collins, C., Pinkel, D., Powell, B., Mills, G. B., & Gray, J. W. (1999) · Nature Genetics · doi:10.1038/5042 · Cited by 1,155
Self-citationShou, J., Massarweh, S., Osborne, C. K., Wakeling, A. E., Ali, S., Weiss, H., & Schiff, R. (2004) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djh166 · Cited by 1,153
Zhou, B. P., Liao, Y., Xia, W., Spohn, B., Lee, M.-H., & Hung, M.-C. (2001) · Nature Cell Biology · doi:10.1038/35060032 · Cited by 1,135
The TSC1-2 tumor suppressor controls insulin–PI3K signaling via regulation of IRS proteins
Harrington, L. S., Findlay, G. M., Gray, A., Tolkacheva, T., Wigfield, S., Rebholz, H., Barnett, J., Leslie, N. R., Cheng, S., Shepherd, P. R., et al. (2004) · The Journal of Cell Biology · doi:10.1083/jcb.200403069 · Cited by 1,123
The LKB1 tumor suppressor negatively regulates mTOR signaling
Shaw, R. J., Bardeesy, N., Manning, B. D., Lopez, L., Kosmatka, M., DePinho, R. A., & Cantley, L. C. (2004) · Cancer Cell · doi:10.1016/j.ccr.2004.06.007 · Cited by 1,077
Rodriguez-Viciana, P., Warne, P. H., Khwaja, A., Marte, B. M., Pappin, D., Das, P., Waterfield, M. D., Ridley, A., & Downward, J. (1997) · Cell · doi:10.1016/s0092-8674(00)80226-3 · Cited by 1,061
The Biochemical Basis of an All-or-None Cell Fate Switch in Xenopus Oocytes
Ferrell, J. E., & Machleder, E. M. (1998) · Science · doi:10.1126/science.280.5365.895 · Cited by 1,052
Enhanced sensitivity of PTEN-deficient tumors to inhibition of FRAP/mTOR
Neshat, M. S., Mellinghoff, I. K., Tran, C., Stiles, B., Thomas, G., Petersen, R., Frost, P., Gibbons, J. J., Wu, H., & Sawyers, C. L. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.171076798 · Cited by 969
Akt regulates growth by directly phosphorylating Tsc2
Potter, C. J., Pedraza, L. G., & Xu, T. (2002) · Nature Cell Biology · doi:10.1038/ncb840 · Cited by 959
Cho, H., Thorvaldsen, J. L., Chu, Q., Feng, F., & Birnbaum, M. J. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.c100462200 · Cited by 959
Malignant transformation by a eukaryotic initiation factor subunit that binds to mRNA 5' cap
Lazaris-Karatzas, A., Montine, K. S., & Sonenberg, N. (1990) · Nature · doi:10.1038/345544a0 · Cited by 956
Survival signalling by Akt and eIF4E in oncogenesis and cancer therapy
Wendel, H.-G., Stanchina, E. D., Fridman, J. S., Malina, A., Ray, S., Kogan, S., Cordon-Cardo, C., Pelletier, J., & Lowe, S. W. (2004) · Nature · doi:10.1038/nature02369 · Cited by 951
Impaired B and T Cell Antigen Receptor Signaling in p110δ PI 3-Kinase Mutant Mice
Okkenhaug, K., Bilancio, A., Farjot, G., Priddle, H., Sancho, S., Peskett, E., Pearce, W., Meek, S. E., Salpekar, A., Waterfield, M. D., et al. (2002) · Science · doi:10.1126/science.1073560 · Cited by 946
AKT plays a central role in tumorigenesis
Testa, J. R., & Bellacosa, A. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.211430998 · Cited by 944
Role of VHL Gene Mutation in Human Cancer
Kim, W. Y., & Kaelin, W. G. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.05.061 · Cited by 943
Atkins, M. B., Hidalgo, M., Stadler, W. M., Logan, T. F., Dutcher, J. P., Hudes, G. R., Park, Y., Liou, S.-H., Marshall, B., Boni, J. P., et al. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.08.185 · Cited by 942
A Retroviral Oncogene, akt , Encoding a Serine-Threonine Kinase Containing an SH2-Like Region
Bellacosa, A., Testa, J. R., Staal, S. P., & Tsichlis, P. N. (1991) · Science · doi:10.1126/science.1833819 · Cited by 939
Mutation of the PIK3CA Gene in Ovarian and Breast Cancer
Campbell, I. G., Russell, S. E., Choong, D. Y. H., Montgomery, K. G., Ciavarella, M. L., Hooi, C. S. F., Cristiano, B. E., Pearson, R. B., & Phillips, W. A. (2004) · Cancer Research · doi:10.1158/0008-5472.can-04-2933 · Cited by 916
Mutant PIK3CA promotes cell growth and invasion of human cancer cells.
Samuels, Y., Diaz, L. A., Schmidt-Kittler, O., Cummins, J. M., DeLong, L., Cheong, I., Rago, C., Huso, D. L., Lengauer, C., Kinzler, K. W., et al. (2005) · Cancer Cell · doi:10.1016/j.ccr.2005.05.014 · Cited by 915
Brognard, J., Clark, A. S., Ni, Y., & Dennis, P. A. (2001) · PubMed · Cited by 905
Management of cellular energy by the AMP‐activated protein kinase system
Hardie, D. G., Scott, J. W., Pan, D. A., & Hudson, E. R. (2003) · FEBS Letters · doi:10.1016/s0014-5793(03)00560-x · Cited by 855
Molecular alterations of the AKT 2 oncogene in ovarian and breast carcinomas
Bellacosa, A., De Feo, D., Godwin, A. K., Bell, D. W., Cheng, J. Q., Altomare, D. A., Wan, M., Dubeau, L., Scambia, G., Masciullo, V., et al. (1995) · International Journal of Cancer · doi:10.1002/ijc.2910640412 · Cited by 837
Tee, A. R., Fingar, D. C., Manning, B. D., Kwiatkowski, D. J., Cantley, L. C., & Blenis, J. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.202476899 · Cited by 827
Peng, X.-D., Xu, P.-Z., Chen, M.-L., Hahn-Windgassen, A., Skeen, J., Jacobs, J., Sundararajan, D., Chen, W. S., Crawford, S. E., Coleman, K. G., et al. (2003) · Genes & Development · doi:10.1101/gad.1089403 · Cited by 826
Phosphatidylinositol 3-kinase mutations identified in human cancer are oncogenic
Kang, S., Bader, A. G., & Vogt, P. K. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0408864102 · Cited by 823
The Akt-mTOR tango and its relevance to cancer
Hay, N. (2005) · Cancer Cell · doi:10.1016/j.ccr.2005.08.008 · Cited by 821
Intragenic ERBB2 kinase mutations in tumours
Stephens, P., Hunter, C., Bignell, G., Edkins, S., Davies, H., Teague, J., Stevens, C., O'Meara, S., Smith, R., Parker, A., et al. (2004) · Nature · doi:10.1038/431525b · Cited by 802
Sun, S.-Y., Rosenberg, L. M., Wang, X., Zhou, Z., Yue, P., Fu, H., & Khuri, F. R. (2005) · Cancer Research · doi:10.1158/0008-5472.can-05-0917 · Cited by 802
Cheng, J. Q., Ruggeri, B., Klein, W. M., Sonoda, G., Altomare, D. A., Watson, D. K., & Testa, J. R. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.8.3636 · Cited by 793
Shin, I., Yakes, F. M., Rojo, F., Shin, N.-Y., Bakin, A. V., Baselga, J., & Arteaga, C. L. (2002) · Nature Medicine · doi:10.1038/nm759 · Cited by 790
PTEN: One Gene, Many Syndromes
Eng, C. (2003) · Human Mutation · doi:10.1002/humu.10257 · Cited by 787
Protein–protein interactions define specificity in signal transduction
Pawson, T., & Nash, P. (2000) · Genes & Development · doi:10.1101/gad.14.9.1027 · Cited by 780
Staal, S. P. (1987) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.84.14.5034 · Cited by 767
Frequent inactivation of PTEN/MMAC1 in primary prostate cancer.
Cairns, P., Okami, K., Halachmi, S., Halachmi, N., Esteller, M., Herman, J. G., Jen, J., Isaacs, W. B., Bova, G. S., & Sidransky, D. (1997) · PubMed · Cited by 700
Phosphatidylinositol 3-kinase: Structure and expression of the 110 kd catalytic subunit
Hiles, I. D., Otsu, M., Volinia, S., Fry, M. J., Gout, I., Dhand, R., Panayotou, G., Ruiz-Larrea, F., Thompson, A., Totty, N. F., et al. (1992) · Cell · doi:10.1016/0092-8674(92)90166-a · Cited by 684
The PIK3CA gene is mutated with high frequency in human breast cancers
Bachman, K. E., Argani, P., Samuels, Y., Silliman, N., Ptak, J., Szabo, S., Konishi, H., Karakas, B., Blair, B. G., Lin, C., et al. (2004) · Cancer Biology & Therapy · doi:10.4161/cbt.3.8.994 · Cited by 665
Sherr, C. J., & Weber, J. D. (2000) · Current Opinion in Genetics & Development · doi:10.1016/s0959-437x(99)00038-6 · Cited by 654
Bhalla, U. S., Ram, P. T., & Iyengar, R. (2002) · Science · doi:10.1126/science.1068873 · Cited by 631
Self-citationEkstrand, A. J., Sugawa, N., James, C. D., & Collins, V. P. (1992) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.89.10.4309 · Cited by 602
Mutations in a signalling pathway
Parsons, D. W., Wang, T.-L., Samuels, Y., Bardelli, A., Cummins, J. M., DeLong, L., Silliman, N., Ptak, J., Szabo, S., Willson, J. K. V., et al. (2005) · Nature · doi:10.1038/436792a · Cited by 599
PI 3-kinase p110β: a new target for antithrombotic therapy
Jackson, S. P., Schoenwaelder, S. M., Goncalves, I., Nesbitt, W. S., Yap, C. L., Wright, C. E., Kenche, V., Anderson, K. E., Dopheide, S. M., Yuan, Y., et al. (2005) · Nature Medicine · doi:10.1038/nm1232 · Cited by 580
Rathmell, J. C., Fox, C. J., Plas, D. R., Hammerman, P. S., Cinalli, R. M., & Thompson, C. B. (2003) · Molecular and Cellular Biology · doi:10.1128/mcb.23.20.7315-7328.2003 · Cited by 572
An inhibitor of mTOR reduces neoplasia and normalizes p70/S6 kinase activity in Pten+/−mice
Podsypanina, K., Lee, R. T., Politis, C., Hennessy, I., Crane, A., Puc, J., Neshat, M., Wang, H., Yang, L., Gibbons, J., et al. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.171060098 · Cited by 569
Loss of Tsc1/Tsc2 activates mTOR and disrupts PI3K-Akt signaling through downregulation of PDGFR
Zhang, H., Cicchetti, G., Onda, H., Koon, H. B., Asrican, K., Bajraszewski, N., Vazquez, F., Carpenter, C. L., & Kwiatkowski, D. J. (2003) · Journal of Clinical Investigation · doi:10.1172/jci17222 · Cited by 538
Mutational Analysis of the Tyrosine Phosphatome in Colorectal Cancers
Wang, Z., Shen, D., Parsons, D. W., Bardelli, A., Sager, J., Szabo, S., Ptak, J., Silliman, N., Peters, B. A., van der Heijden, M. S., et al. (2004) · Science · doi:10.1126/science.1096096 · Cited by 522
Allosteric Akt (PKB) inhibitors: discovery and SAR of isozyme selective inhibitors
Lindsley, C. W., Zhao, Z., Leister, W. H., Robinson, R. G., Barnett, S. F., Defeo-Jones, D., Jones, R. E., Hartman, G. D., Huff, J. R., Huber, H. E., et al. (2005) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2004.11.011 · Cited by 503
Debiec-Rychter, M., Cools, J., Dumez, H., Sciot, R., Stul, M., Mentens, N., Vranckx, H., Wasag, B., Prenen, H., Roesel, J., et al. (2005) · Gastroenterology · doi:10.1053/j.gastro.2004.11.020 · Cited by 494
COFFER, P. J., & WOODGETT, J. R. (1991) · European Journal of Biochemistry · doi:10.1111/j.1432-1033.1991.tb16305.x · Cited by 487
Somatic Mutations of the Protein Kinase Gene Family in Human Lung Cancer
Davies, H., Hunter, C., Smith, R., Stephens, P., Greenman, C., Bignell, G., Teague, J., Butler, A., Edkins, S., Stevens, C., et al. (2005) · Cancer Research · doi:10.1158/0008-5472.can-05-1855 · Cited by 469
The role of phosphoinositide-3 kinase and PTEN in cardiovascular physiology and disease
OUDIT, G. (2004) · Journal of Molecular and Cellular Cardiology · doi:10.1016/j.yjmcc.2004.05.015 · Cited by 469
Bi, L., Okabe, I., Bernard, D. J., Wynshaw-Boris, A., & Nussbaum, R. L. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.16.10963 · Cited by 452
HER2/PI-3K/Akt activation leads to a multidrug resistance in human breast adenocarcinoma cells
Knuefermann, C., Lu, Y., Liu, B., Jin, W., Liang, K., Wu, L., Schmidt, M., Mills, G. B., Mendelsohn, J., & Fan, Z. (2003) · Oncogene · doi:10.1038/sj.onc.1206394 · Cited by 452
Self-citationPIK3CA as an oncogene in cervical cancer
Ma, Y.-Y., Wei, S.-J., Lin, Y.-C., Lung, J.-C., Chang, T.-C., Whang-Peng, J., Liu, J. M., Yang, D.-M., Yang, W. K., & Shen, C.-Y. (2000) · Oncogene · doi:10.1038/sj.onc.1203597 · Cited by 434
Arboleda, M. J., Lyons, J. F., Kabbinavar, F. F., Bray, M. R., Snow, B. E., Ayala, R., Danino, M., Karlan, B. Y., & Slamon, D. J. (2003) · PubMed · Cited by 417
Phosphoinositide 3-kinase signalling – which way to target?
Wymann, M. P., Zvelebil, M., & Laffargue, M. (2003) · Trends in Pharmacological Sciences · doi:10.1016/s0165-6147(03)00163-9 · Cited by 411
Perifosine, a novel alkylphospholipid, inhibits protein kinase B activation.
Kondapaka, S. B., Singh, S. S., Dasmahapatra, G. P., Sausville, E. A., & Roy, K. (2003) · PubMed · Cited by 407
BARNETT, S. F., DEFEO-JONES, D., FU, S., HANCOCK, P. J., HASKELL, K. M., JONES, R. E., KAHANA, J. A., KRAL, A. M., LEANDER, K., LEE, L. L., et al. (2005) · Biochemical Journal · doi:10.1042/bj20041140 · Cited by 396
deGraffenried, L. A., Friedrichs, W. E., Russell, D. H., Donzis, E. J., Middleton, A. K., Silva, J. M., Roth, R. A., & Hidalgo, M. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-0035 · Cited by 387
Protein Kinase Bα/Akt1 Regulates Placental Development and Fetal Growth
Yang, Z.-Z., Tschopp, O., Hemmings-Mieszczak, M., Feng, J., Brodbeck, D., Perentes, E., & Hemmings, B. A. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m302847200 · Cited by 384
PKB/Akt modulates TGF-β signalling through a direct interaction with Smad3
Remy, I., Montmarquette, A., & Michnick, S. W. (2004) · Nature Cell Biology · doi:10.1038/ncb1113 · Cited by 372
Hu, L., Hofmann, J., Lu, Y., Mills, G. B., & Jaffe, R. B. (2002) · PubMed · Cited by 361
Self-citationActivity of rapamycin (AY-22,989) against transplanted tumors.
ENG, C. P., SEHGAL, S. N., & VEZINA, C. (1984) · The Journal of Antibiotics · doi:10.7164/antibiotics.37.1231 · Cited by 351
Mutations of PIK3CA in Anaplastic Oligodendrogliomas, High-Grade Astrocytomas, and Medulloblastomas
Broderick, D. K., Di, C., Parrett, T. J., Samuels, Y. R., Cummins, J. M., McLendon, R. E., Fults, D. W., Velculescu, V. E., Bigner, D. D., & Yan, H. (2004) · Cancer Research · doi:10.1158/0008-5472.can-04-1170 · Cited by 337
Formation of Regulatory Patterns During Signal Propagation in a Mammalian Cellular Network
Ma'ayan, A., Jenkins, S. L., Neves, S., Hasseldine, A., Grace, E., Dubin-Thaler, B., Eungdamrong, N. J., Weng, G., Ram, P. T., Rice, J. J., et al. (2005) · Science · doi:10.1126/science.1108876 · Cited by 335
Self-citationStephens, P., Edkins, S., Davies, H., Greenman, C., Cox, C., Hunter, C., Bignell, G., Teague, J., Smith, R., Stevens, C., et al. (2005) · Nature Genetics · doi:10.1038/ng1571 · Cited by 332
Kau, T. R., Schroeder, F., Ramaswamy, S., Wojciechowski, C. L., Zhao, J. J., Roberts, T. M., Clardy, J., Sellers, W. R., & Silver, P. A. (2003) · Cancer Cell · doi:10.1016/s1535-6108(03)00303-9 · Cited by 329
Ruggeri, B. A., Huang, L., Wood, M., Cheng, J. Q., & Testa, J. R. (1998) · Molecular Carcinogenesis · doi:10.1002/(sici)1098-2744(199802)21:2<81::aid-mc1>3.3.co;2-k · Cited by 329
Mondesire, W. H., Jian, W., Zhang, H., Ensor, J., Hung, M.-C., Mills, G. B., & Meric-Bernstam, F. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-0361 · Cited by 319
Self-citationMukohara, T., Engelman, J. A., Hanna, N. H., Yeap, B. Y., Kobayashi, S., Lindeman, N., Halmos, B., Pearlberg, J., Tsuchihashi, Z., Cantley, L. C., et al. (2005) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/dji238 · Cited by 318
Somatic Mutations of EGFR in Colorectal Cancers and Glioblastomas
Barber, T. D., Vogelstein, B., Kinzler, K. W., & Velculescu, V. E. (2004) · New England Journal of Medicine · doi:10.1056/nejm200412303512724 · Cited by 315
Pardanani, A., Brockman, S. R., Paternoster, S. F., Flynn, H. C., Ketterling, R. P., Lasho, T. L., Ho, C.-L., Li, C.-Y., Dewald, G. W., & Tefferi, A. (2004) · Blood · doi:10.1182/blood-2004-03-0787 · Cited by 309
Goel, A., Arnold, C. N., Niedzwiecki, D., Carethers, J. M., Dowell, J. M., Wasserman, L., Compton, C., Mayer, R. J., Bertagnolli, M. M., & Boland, C. R. (2004) · Cancer Research · doi:10.1158/0008-5472.can-2401-2 · Cited by 302
Hu, L., Zaloudek, C. J., Mills, G. B., Gray, J. W., & Jaffe, R. B. (2000) · PubMed · Cited by 301
Self-citationConstitutively active Akt is an important regulator of TRAIL sensitivity in prostate cancer
Chen, X., Thakkar, H., Tyan, F., Gim, S., Robinson, H., Lee, C., Pandey, S. K., Nwokorie, C., Onwudiwe, N., & Srivastava, R. K. (2001) · Oncogene · doi:10.1038/sj.onc.1204736 · Cited by 298
Condliffe, A. M. (2005) · Blood · doi:10.1182/blood-2005-03-0944 · Cited by 295
Clinical role of positron emission tomography in oncology
Bomanji, J., Costa, D., & Ell, P. (2001) · The Lancet Oncology · doi:10.1016/s1470-2045(00)00257-6 · Cited by 281
Shepherd, F. A., Pereira, J. R., Ciuleanu, T., Tan, E. H., Hirsh, V., Thongprasert, S., Bezjak, A., Tu, D., Santabarbara, P., & Seymour, L. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.22.14_suppl.7022 · Cited by 281
Carroll, P. E., Okuda, M., Horn, H. F., Biddinger, P., Stambrook, P. J., Gleich, L. L., Li, Y.-Q., Tarapore, P., & Fukasawa, K. (1999) · Oncogene · doi:10.1038/sj.onc.1202515 · Cited by 279
Jimenez, C. (1998) · The EMBO Journal · doi:10.1093/emboj/17.3.743 · Cited by 269
Chantry, D., Vojtek, A., Kashishian, A., Holtzman, D. A., Wood, C., Gray, P. W., Cooper, J. A., & Hoekstra, M. F. (1997) · Journal of Biological Chemistry · doi:10.1074/jbc.272.31.19236 · Cited by 253
Sujobert, P. (2005) · Blood · doi:10.1182/blood-2004-08-3225 · Cited by 245
Dudkin, L., Dilling, M. B., Cheshire, P. J., Harwood, F. C., Hollingshead, M. G., Arbuck, S. G., Travis, R., Sausville, E. A., & Houghton, P. J. (2001) · PubMed · Cited by 232
Rapamycin enhances apoptosis and increases sensitivity to cisplatin in vitro.
Shi, Y., Frankel, A., Radvanyi, L. G., Penn, L. Z., Miller, R. G., & Mills, G. B. (1995) · PubMed · Cited by 225
Self-citationCahill, C. M., Tzivion, G., Nasrin, N., Ogg, S., Dore, J., Ruvkun, G., & Alexander-Bridges, M. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m010042200 · Cited by 219
Lynch, D. K., Ellis, C. A., Edwards, P. A., & Hiles, I. D. (1999) · Oncogene · doi:10.1038/sj.onc.1203258 · Cited by 214
Bilancio, A., Okkenhaug, K., Camps, M., Emery, J. L., Ruckle, T., Rommel, C., & Vanhaesebroeck, B. (2006) · Blood · doi:10.1182/blood-2005-07-3041 · Cited by 212
Rosenzweig, K., Youmell, M. B., Palayoor, S. T., et al. (1997) · PubMed · Cited by 210
Fujita, N., Sato, S., & Tsuruo, T. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m306614200 · Cited by 209
Lu, Y., Zi, X., & Pollak, M. (2004) · International Journal of Cancer · doi:10.1002/ijc.11445 · Cited by 208
Self-citationThompson, J. E., & Thompson, C. B. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.01.103 · Cited by 206
AKT/PKB signaling mechanisms in cancer and chemoresistance
Kim, D. (2005) · Frontiers in Bioscience · doi:10.2741/1592 · Cited by 204
(2001) · PubMed · Cited by 193
Skinner, H. D., Zheng, J. Z., Fang, J., Agani, F., & Jiang, B.-H. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m404097200 · Cited by 192
Gupta, A. K., Cerniglia, G. J., Mick, R., Ahmed, M. S., Bakanauskas, V. J., Muschel, R. J., & McKenna, W. G. (2003) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/s0360-3016(03)00214-1 · Cited by 184
Brachmann, S. M., Ueki, K., Engelman, J. A., Kahn, R. C., & Cantley, L. C. (2005) · Molecular and Cellular Biology · doi:10.1128/mcb.25.5.1596-1607.2005 · Cited by 179
deGraffenried, L. A., Fulcher, L., Friedrichs, W. E., Grünwald, V., Ray, R. B., & Hidalgo, M. (2004) · Annals of Oncology · doi:10.1093/annonc/mdh388 · Cited by 177
Stoica, G. E., Franke, T. F., Moroni, M., Mueller, S., Morgan, E., Iann, M. C., Winder, A. D., Reiter, R., Wellstein, A., Martin, M. B., et al. (2003) · Oncogene · doi:10.1038/sj.onc.1206769 · Cited by 173
DeFeo-Jones, D., Barnett, S. F., Fu, S., Hancock, P. J., Haskell, K. M., Leander, K. R., McAvoy, E., Robinson, R. G., Duggan, M. E., Lindsley, C. W., et al. (2005) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.271.4.2 · Cited by 173
Kawakami, Y., Nishimoto, H., Kitaura, J., Maeda-Yamamoto, M., Kato, R. M., Littman, D. R., Rawlings, D. J., & Kawakami, T. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m408797200 · Cited by 166
The von Hippel–Lindau Protein, Vascular Endothelial Growth Factor, and Kidney Cancer
George, D. J., & Kaelin, W. G. (2003) · New England Journal of Medicine · doi:10.1056/nejmp030061 · Cited by 165
Van Ummersen, L., Binger, K., Volkman, J., Marnocha, R., Tutsch, K., Kolesar, J., Arzoomanian, R., Alberti, D., & Wilding, G. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-03-0406 · Cited by 158
PATHWAY LOGIC: SYMBOLIC ANALYSIS OF BIOLOGICAL SIGNALING
Eker, S., Knapp, M., Laderoute, K. R., Lincoln, P. D., Meseguer, J., & Sönmez, K. (2001) · Pacific Symposium on Biocomputing (PSB) · doi:10.1142/9789812799623_0038 · Cited by 157
Woenckhaus, J., Steger, K., Werner, E., Fenic, I., Gamerdinger, U., Dreyer, T., & Stahl, U. (2002) · The Journal of Pathology · doi:10.1002/path.1207 · Cited by 152
Zhang, D., & Brodt, P. (2003) · Oncogene · doi:10.1038/sj.onc.1206197 · Cited by 149
Méndez, P., Azcoitia, Í., & García‐Segura, L. M. (2003) · Molecular Brain Research · doi:10.1016/s0169-328x(03)00088-3 · Cited by 147
Kimura, A., Ohmichi, M., Kawagoe, J., Kyo, S., Mabuchi, S., Takahashi, T., Ohshima, C., Arimoto‐Ishida, E., Nishio, Y., Inoue, M., et al. (2004) · Oncogene · doi:10.1038/sj.onc.1207582 · Cited by 146
Isoform-specific phosphoinositide 3-kinase inhibitors as therapeutic agents
Ward, S. G., & Finan, P. (2003) · Current Opinion in Pharmacology · doi:10.1016/s1471-4892(03)00078-x · Cited by 139
Isoform-specific phosphoinositide 3-kinase inhibitors from an arylmorpholine scaffold
Knight, Z. A., Chiang, G. G., Alaimo, P. J., Kenski, D. M., Ho, C., Coan, K., Abraham, R. T., & Shokat, K. M. (2004) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2004.06.022 · Cited by 137
Genetic Alterations of Phosphoinositide 3‐kinase Subunit Genes in Human Glioblastomas
Mizoguchi, M., Nutt, C. L., Mohapatra, G., & Louis, D. N. (2004) · Brain Pathology · doi:10.1111/j.1750-3639.2004.tb00080.x · Cited by 136
Mills, G. B., Lu, Y., & Kohn, E. C. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.191379498 · Cited by 126
Self-citationPTEN promoter is methylated in a proportion of invasive breast cancers
Khan, S., Kumagai, T., Vora, J., Bose, N., Sehgal, I., Koeffler, H. P., & Bose, S. (2004) · International Journal of Cancer · doi:10.1002/ijc.20447 · Cited by 125
Allelic loss of the PTEN region (10q23) in breast carcinomas of poor pathophenotype
Garcia, J. M., Silva, J. M., Domínguez, G., Gonzalez, R. M., Navarro, A., Carretero, L., Provencio, M., España, P., & Bonilla, F. (1999) · Breast Cancer Research and Treatment · doi:10.1023/a:1006273516976 · Cited by 122
Evaluation of response: new and standard criteria
Therasse, P. (2002) · Annals of Oncology · doi:10.1093/annonc/mdf649 · Cited by 120
Translational Control of the Antiapoptotic Function of Ras
Polunovsky, V. A., Gingras, A., Sonenberg, N., Peterson, M., Tan, A., Rubins, J. B., Manivel, J. C., & Bitterman, P. B. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.m001938200 · Cited by 117
In vitro and in vivo antitumor activity of the phosphatidylinositol-3-kinase inhibitor, wortmannin.
Schultz, R. M., Merriman, R. L., Andis, S. L., Bonjouklian, R., Grindey, G. B., Rutherford, P., Gallegos, A. C., Massey, K. L., & Powis, G. (1995) · PubMed · Cited by 113
Klos, K. S., Zhou, X., Lee, S., Zhang, L., Yang, W., Nagata, Y., & Yu, D. (2003) · Cancer · doi:10.1002/cncr.11656 · Cited by 111
Wang, Q., Wang, X., Hernandez, A., Hellmich, M. R., Gatalica, Z., & Evers, B. M. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m206306200 · Cited by 109
Samuelson, A. V., & Lowe, S. W. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.22.12094 · Cited by 102
Park, C. S., Schneider, I., & Haugh, J. M. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m304968200 · Cited by 101
Leverrier, Y., Okkenhaug, K., Sawyer, C., Bilancio, A., Vanhaesebroeck, B., & Ridley, A. J. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m306649200 · Cited by 92
Jücker, M., Südel, K. M., Horn, S., Sickel, M. J., Wegner, W., Fiedler, W., & Feldman, R. A. (2002) · Leukemia · doi:10.1038/sj.leu.2402484 · Cited by 87
Gukovsky, I., Cheng, J. H., Nam, K. J., Lee, O. T., Lugea, A., Fischer, L., Penninger, J. M., Pandol, S. J., & Gukovskaya, A. S. (2004) · Gastroenterology · doi:10.1053/j.gastro.2003.11.017 · Cited by 84
Meric‐Bernstam, F. (2004) · Seminars in Oncology · doi:10.1053/j.seminoncol.2004.10.013 · Cited by 76
Detection of K-ras gene mutations in non-neoplastic lung tissue and lung cancers
Nelson, M. A., Wymer, J. A., & Clements, N. C. (1996) · Cancer Letters · doi:10.1016/0304-3835(96)04202-4 · Cited by 74
Biomarkers to Predict Response to Epidermal Growth Factor Receptor Inhibitors
Haas-Kogan, D. A., Prados, M. D., Lamborn, K. R., Tihan, T., Berger, M. S., & Stokoe, D. (2005) · Cell Cycle · doi:10.4161/cc.4.10.2105 · Cited by 70
ASCO 2020 Gastrointestinal Cancers Symposium
Pinion, S. (2020) · The Lancet. Gastroenterology & hepatology · doi:10.1016/s2468-1253(20)30045-5 · Cited by 69
Campbell, M., Allen, W. E., Sawyer, C., Vanhaesebroeck, B., & Trimble, E. R. (2004) · Circulation Research · doi:10.1161/01.res.0000138019.82184.5d · Cited by 68
Murthy, S. S., Tosolini, A., Taguchi, T., & Testa, J. R. (2000) · Cytogenetic and Genome Research · doi:10.1159/000015481 · Cited by 62
Nicholson, K. M., Streuli, C. H., & Anderson, N. G. (2003) · Breast Cancer Research and Treatment · doi:10.1023/a:1025765215765 · Cited by 59
Perrino, C., Prasad, S. V. N., Patel, M. M., Wolf, M. J., & Rockman, H. A. (2005) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2005.02.062 · Cited by 51
Geng, L., Tan, J., Himmelfarb, E. A., Schueneman, A. J., Niermann, K. J., Fu, A., Cuneo, K. C., Kesicki, E. A., Treiberg, J., Hayflick, J. S., et al. (2004) · Cancer Research · doi:10.1158/0008-5472.can-03-3955 · Cited by 47
Kim, S., Um, J.-H., Kim, D., Kwon, B., Kim, D.-W., Chung, B.-S., & Kang, C.-D. (2000) · Leukemia Research · doi:10.1016/s0145-2126(00)00061-8 · Cited by 46
Therapeutic potential of phosphoinositide 3-kinase inhibitors
Drees, B. E., Mills, G. B., Rommel, C., & Prestwich, G. D. (2004) · Expert Opinion on Therapeutic Patents · doi:10.1517/13543776.14.5.703 · Cited by 37
Self-citationRapamycin inhibits Akt-mediated oncogenic transformation and tumor growth.
Liu, X., Powlas, J. A., Shi, Y., Oleksijew, A., Shoemaker, A. R., de Jong, R., Oltersdorf, T., Giranda, V. L., & Luo, Y. (2004) · PubMed · Cited by 30
Tuberous sclerosis genes regulate cellular 14-3-3 protein levels
Hengstschläger, M., Rosner, M., Fountoulakis, M., & Lübec, G. (2003) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2003.10.170 · Cited by 27
Molecular therapeutics: promise and challenges
Kohn, E. C., Lu, Y., Wang, H., Yu, Q., Yu, S., Hall, H. S., Smith, D. L., Meric‐Bernstam, F., Hortobágyi, G. N., & Mills, G. B. (2004) · Seminars in Oncology · doi:10.1053/j.seminoncol.2004.01.009 · Cited by 24
Self-citationToi, M., Saji, S., Suzuki, A., Yamamoto, Y., & Tominaga, T. (1997) · Breast Cancer · doi:10.1007/bf02966519 · Cited by 16
Cited by
Targeting the phosphoinositide 3-kinase pathway in cancer
Liu, P., Cheng, H., Roberts, T. M., & Zhao, J. J. (2009) · Nature Reviews Drug Discovery · doi:10.1038/nrd2926 · Cited by 2,721
PI3K/AKT/mTOR signaling transduction pathway and targeted therapies in cancer
Glaviano, A., Foo, A. S. C., Lam, H. Y., Yap, K. C. H., Jacot, W., Jones, R. H., Eng, H., Nair, M. G., Makvandi, P., Geoerger, B., et al. (2023) · Molecular Cancer · doi:10.1186/s12943-023-01827-6 · Cited by 2,138
Targeting PI3K/Akt signal transduction for cancer therapy
He, Y., Sun, M. M., Zhang, G. G., Yang, J., Chen, K. S., Xu, W. W., & Li, B. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00828-5 · Cited by 1,892
Phosphoinositides: Tiny Lipids With Giant Impact on Cell Regulation
Balla, T. (2013) · Physiological Reviews · doi:10.1152/physrev.00028.2012 · Cited by 1,638
Hyperactive Ras in developmental disorders and cancer
Schubbert, S., Shannon, K., & Bollag, G. (2007) · Nature Reviews Cancer · doi:10.1038/nrc2109 · Cited by 1,583
Metadata
- Authors
- Hennessy, B. T., Smith, D. L., Ram, P. T., Lu, Y., & Mills, G. B.
- Venue
- Nature Reviews Drug Discovery
- Published
- 2005-12
- Volume
- 4
- Issue
- 12
- Pages
- 988-1004
- ISSN
- 1474-1776 (ISSN-L)
- 1474-1784
- OpenAlex
- W2087861588
- Cited by
- 2,185
- References
- 165
- FWCI
- 4.28
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.